Progestogens in Prostatic Cancer
- 1 January 1978
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 4 (3) , 162-166
- https://doi.org/10.1159/000473940
Abstract
A series of 20 patients with a histological diagnosis of prostatic cancer were treated with high doses of MAP (6α-methyl-17α-hydroxyprogesterone acetate). No response was noted in 9 patients with prostatic cancer in relapse. Objective and/or subjective response was noted in 6 of 11 patients who were untreated at the time of diagnosis.Keywords
This publication has 0 references indexed in Scilit: